Fierce Biotech2d
Equillium misses primary endpoint, plus 2 key secondaries, but still plans approval filing
Equillium’s phase 3 graft-versus-host disease (GVHD) trial has missed its primary endpoint and two key secondary objectives.
EurekAlert!4d
PP2A regulates CD8+ T cell effector functions through AKT signaling pathway: implications for immunotherapy
A groundbreaking study published in Research (2025, DOI: 10.34133/research.0545) has elucidated the molecular mechanisms by which protein phosphatase 2A (PP2A) regulates CD8+ T cell-mediated immune ...
Portage Biotech Reports Promising Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7
About Portage Biotech Portage Biotech is a clinical-stage immuno-oncology company advancing a pipeline of novel biologics to transform the immune system’s ability to fight cancer. For more information ...
Portage Biotech presents preclinical data for PORT-7
Portage Biotech (PRTG) presented new preclinical data for PORT-7, a selective Adenosine A2B receptor inhibitor. The new data demonstrate both ...
CURE8d
FDA Grants Fast Track Designation for Azer-Cel in Lymphoma Subset
FDA grants fast track designation to azer-cel, an allogeneic CAR T-cell therapy, for relapsed or refractory diffuse large ...
Fierce Biotech9d
Regulatory T-cell therapy calms autoimmune response from gluten-sensitive T cells in mice
For the 80 million people worldwide with celiac disease, the only treatment available is to cut grains like pasta and bread out of their lives. | For the 80 million people worldwide who have celiac ...